ADAG

Adagene Inc ADR

2.41

Oct 21 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology China Micro NASD

Peers: CTMX JANX MGNX XNCR CGEN ANL BCYC IPHA AAPG ETRA

Index	-
Market Cap	161.81M
Enterprise Value	56.54M
Income	-20.56M
Sales	9.32M
Book/sh	1.33
Cash/sh	1.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	128
IPO	Feb 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	17.36
P/B	1.81
P/C	1.27
P/FCF	-
EV/EBITDA	-
EV/Sales	6.07
Quick Ratio	5.02
Current Ratio	5.02
Debt/Eq	0.06
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.38
EPS next Y	-0.64
EPS next Q	-0.28
EPS this Y	-60.00%
EPS next Y	-34.17%
EPS next 5Y	-
EPS past 3/5Y	41.25% 21.03%
Sales past 3/5Y	-6.07% 61.40%
EPS Y/Y TTM	41.48%
Sales Y/Y TTM	8906.15%
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	- -

Insider Own	18.49%
Insider Trans	0.38%
Inst Own	18.74%
Inst Trans	40.63%
ROA	-20.55%
ROE	-28.57%
ROIC	-19.17%
Gross Margin	94.22%
Oper. Margin	-240.31%
Profit Margin	-220.66%
SMA20	-11.61%
SMA50	-25.64%
SMA200	-29.00%
Trades

Shs Outstand	67.14M
Shs Float	54.73M
Short Float	3.86%
Short Ratio	7.36
Short Interest	2.11M
52W High	4.85 -50.31%
52W Low	1.30 85.38%
Volatility	11.16% 10.37%
ATR (14)	0.27
RSI (14)	39.10
Beta	0.65
Rel Volume	0.00
Avg Volume	287.34K
Volume	0

Perf Week	5.24%
Perf Month	-25.39%
Perf Quarter	-28.49%
Perf Half Y	-36.24%
Perf YTD	27.51%
Perf Year	27.51%
Perf 3Y	72.14%
Perf 5Y	-80.16%
Perf 10Y	-
Recom	1.00
Target Price	9.74
Prev Close	2.41
Price	2.41
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-26	Initiated	Chardan Capital Markets	Buy	$9
Nov-24-25	Initiated	Guggenheim	Buy	$9
Aug-06-25	Initiated	Leerink Partners	Outperform	$7
Jan-31-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-25-21	Initiated	China Renaissance	Buy	$40.57
Mar-08-21	Initiated	Morgan Stanley	Overweight	$34
Mar-08-21	Initiated	Jefferies	Buy	$33
Mar-08-21	Initiated	Goldman	Buy	$29

Oct-14-26 08:00AM	Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.91%
Sep-22-26 08:00AM	Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager (GlobeNewswire)
Sep-10-26 08:00AM	Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody Technology (GlobeNewswire)
Sep-09-26 08:00AM	Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates (GlobeNewswire) -6.30%
Aug-20-26 08:00AM	Adagene to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
Aug-12-26 07:30AM	Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-12-26 08:30AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Apr-17-26 04:01PM	Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types (GlobeNewswire)
Apr-14-26 07:00AM	Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board (GlobeNewswire)
Apr-02-26 07:10AM	Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs (GlobeNewswire) -13.45%
07:01AM	Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) (GlobeNewswire)
07:00AM	Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response (GlobeNewswire)
Apr-01-26 05:00PM	Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.60%
Mar-17-26 04:35PM	Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA (GlobeNewswire)
Feb-25-26 05:25PM	Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk (MarketBeat) -5.67%
09:27AM	Loading…
Feb-17-26 09:27AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-16-26 07:48AM	Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders (Zacks)
Jan-23-26 08:00AM	Adagene Provides Business Update and 2026 Objectives (GlobeNewswire) +22.66%
Dec-17-25 08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
Dec-16-25 07:00AM	Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) (GlobeNewswire) +13.77%
Nov-13-25 07:00AM	Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology (GlobeNewswire)
Oct-31-25 07:00AM	Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer (GlobeNewswire) -7.29%
Sep-30-25 12:00PM	All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy (Zacks)
Sep-25-25 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Sep-16-25 08:00AM	Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Sep-08-25 04:59PM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) +8.64%
Sep-05-25 09:55AM	Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China (GlobeNewswire)
Sep-03-25 09:05AM	Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor (GlobeNewswire)
Aug-26-25 08:05AM	Adagene to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-21-25 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
04:05PM	Loading…
Aug-12-25 04:05PM	Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -16.59% -13.61%
Jul-15-25 07:00AM	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA (GlobeNewswire)
Jul-08-25 07:00AM	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate (GlobeNewswire)
Jul-01-25 07:00AM	Adagene announces up to $25 million strategic investment from Sanofi (GlobeNewswire) -5.13%
Jun-03-25 09:40AM	Is McKesson (MCK) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:30AM	Adagene to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-22-25 05:05PM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.00%
Apr-28-25 08:00AM	Adagene Appoints John Maraganore, Ph.D. as Executive Advisor (GlobeNewswire)
Apr-23-25 10:05AM	Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-07-25 08:00AM	Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum (GlobeNewswire)
Mar-24-25 08:00AM	Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.04%
Mar-13-25 08:00AM	Adagene to Present at 11th Annual Immuno-Oncology 360 Summit (GlobeNewswire)
Mar-06-25 08:00AM	Adagene to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire)
Feb-27-25 08:00AM	Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer (GlobeNewswire)
Jan-27-25 07:00AM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-21-25 05:00PM	Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-14-25 08:00AM	Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 (GlobeNewswire)
Jan-08-25 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.34%
Dec-06-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Nov-20-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.86%
Nov-07-24 10:01AM	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Oct-09-24 06:00AM	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-16-24 03:01AM	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) -21.20%
Sep-11-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-29-24 07:00AM	Adagene to Participate in Investor Conferences in September (GlobeNewswire)
Aug-26-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-25-24 04:05PM	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update (GlobeNewswire) -7.50%
Jul-12-24 07:00AM	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September (GlobeNewswire)
May-22-24 04:45PM	Adagene to Present at Investor Conferences in June (GlobeNewswire) +6.90%
Mar-29-24 09:00AM	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-24 04:01PM	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board (GlobeNewswire)
Feb-27-24 08:00AM	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-09-24 06:00AM	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +5.14%
Jan-17-24 07:00AM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (PR Newswire) +5.82%
Jan-16-24 05:01PM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +19.24%
Jan-04-24 05:00AM	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium (GlobeNewswire)
Nov-03-23 12:00PM	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 at SITC 2023 (GlobeNewswire)
Oct-30-23 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-13-23 09:40AM	Are Medical Stocks Lagging Medpace (MEDP) This Year? (Zacks)
Oct-12-23 08:00AM	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.04%
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Sep-07-23 10:45PM	Adagene to Present at Investor and Scientific Conferences in September (PR Newswire)
09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-31-23 07:32AM	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update (GlobeNewswire) +15.25%
May-25-23 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.22%
May-04-23 09:00AM	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Apr-28-23 07:00AM	Adagene Announces Updates to its Board of Directors (GlobeNewswire)
Apr-18-23 09:17AM	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors (GlobeNewswire)
Mar-31-23 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
06:34AM	Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021) (Simply Wall St.)
Mar-28-23 04:30PM	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.84%
Mar-14-23 06:00PM	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April (GlobeNewswire) +5.15% +11.89%
Mar-05-23 07:39PM	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board (GlobeNewswire)
Jan-09-23 07:00AM	Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial (GlobeNewswire) +11.25%
Jan-05-23 04:01PM	Adagene to Present at the Biotech Showcase 2023 in San Francisco on January 9 (GlobeNewswire) +5.11% +11.11%
Dec-16-22 06:30AM	Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roches Standard-of-Care for First-Line Advanced Liver Cancer (GlobeNewswire) +10.61%
Nov-21-22 04:05PM	Adagene Appoints Cuong Do to Board of Directors and Audit Committee (GlobeNewswire)
Nov-10-22 09:05AM	Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors (GlobeNewswire)
Oct-11-22 04:03PM	Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancers (SITC) Annual Meeting in November (GlobeNewswire) -7.63% +6.61%
Sep-10-22 04:13AM	Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors (GlobeNewswire)
Aug-30-22 05:25PM	Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates (GlobeNewswire)
Jun-29-22 04:05PM	Adagene Announces Authorization of Share Repurchase Program up to US$10 Million (GlobeNewswire)
May-26-22 09:30PM	Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels (PR Newswire)
May-12-22 07:00AM	Adagene to Participate in Investor Conferences in May and June (GlobeNewswire)
May-02-22 06:06AM	Shareholders in Adagene (NASDAQ:ADAG) are in the red if they invested a year ago (Simply Wall St.)
Apr-08-22 01:09PM	Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Apr-03-22 02:34PM	10 Best Non-Tech Chinese Stocks to Buy Now (Insider Monkey)
Mar-31-22 08:30AM	Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 10:42AM	Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo (Zacks)
Mar-16-22 10:00AM	Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors (Benzinga)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tam Man Kin	Chief Financial Officer	Sep 23 '26	Buy	3.00	2,000	6,000	12,000	Sep 25 06:23 PM
Luo Peter	Chief Executive Officer	Sep 16 '26	Buy	3.15	20,290	63,980	88,535	Sep 17 06:11 AM
GU CHUNFANG	Officer	Aug 20 '26	Proposed Sale	3.95	40,000	158,000		Aug 19 10:22 AM
DO CUONG V	Director	Aug 14 '26	Buy	3.75	2,000	7,500	2,000	Aug 18 06:11 PM
Luo Peter	Chief Executive Officer	Aug 04 '26	Buy	3.65	22,966	83,746	67,966	Aug 06 06:15 PM
Luo Peter	Chief Executive Officer	Aug 05 '26	Buy	3.65	279	1,018	68,245	Aug 06 06:15 PM

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Co- FounderDr. Peter P. Luo Ph.D.

CFO & DirectorMr. Man Kin Tam M.B.A.

Executive Director & Head of Human ResourcesMs. Ling Zhou

Chief Manufacturing OfficerDr. Qinghai Zhao Ph.D.

Chief Strategy OfficerMr. Mickael Chane-Du

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADAG

Adagene Inc ADR

Upgrade your Finviz experience